Neuren Pharmaceuticals Limited – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 64
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NFE814AA865EN
Leaflet:

Download PDF Leaflet

Neuren Pharmaceuticals Limited – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Neuren Pharmaceuticals Limited - Product Pipeline Review - H2 2011” provides data on the Neuren Pharmaceuticals Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Neuren Pharmaceuticals Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Neuren Pharmaceuticals Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Neuren Pharmaceuticals Limited - Brief Neuren Pharmaceuticals Limited overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Neuren Pharmaceuticals Limited human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Neuren Pharmaceuticals Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Neuren Pharmaceuticals Limited’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Neuren Pharmaceuticals Limited’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Neuren Pharmaceuticals Limited in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Neuren Pharmaceuticals Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Neuren Pharmaceuticals Limited.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Neuren Pharmaceuticals Limited and identify potential opportunities in those areas.
Neuren Pharmaceuticals Limited Snapshot
Neuren Pharmaceuticals Limited Overview
Key Information
Key Facts
Neuren Pharmaceuticals Limited – Research and Development Overview
Key Therapeutic Areas
Neuren Pharmaceuticals Limited – Pipeline Review
Pipeline Products by Stage of Development
Neuren Pharmaceuticals Limited – Pipeline Products Glance
Neuren Pharmaceuticals Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Neuren Pharmaceuticals Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Neuren Pharmaceuticals Limited – Drug Profiles
Anti TFF-1 Monoclonal Antibody
  Product Description
  Mechanism of Action
  R&D Progress
Anti TFF-3 Monoclonal Antibody
  Product Description
  Mechanism of Action
  R&D Progress
NNZ-2566
  Product Description
  Mechanism of Action
  R&D Progress
NNZ-2591
  Product Description
  Mechanism of Action
  R&D Progress
NNZ-8000
  Product Description
  Mechanism of Action
  R&D Progress
Neuren Pharmaceuticals Limited – Pipeline Analysis
Neuren Pharmaceuticals Limited – Pipeline Products by Therapeutic Class
Neuren Pharmaceuticals Limited - Pipeline Products By Target
Neuren Pharmaceuticals Limited – Pipeline Products by Route of Administration
Neuren Pharmaceuticals Limited – Pipeline Products by Molecule Type
Neuren Pharmaceuticals Limited – Recent Pipeline Updates
Neuren Pharmaceuticals Limited - Dormant Projects
Neuren Pharmaceuticals Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Glypromate
Neuren Pharmaceuticals Limited – Company Statement
Neuren Pharmaceuticals Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 20, 2006: Positive Preclinical Result For Neuren Compound NNZ-3006
Oct 16, 2006: Neuren Annouces That NNZ-2591 Proves Effective At Reversing Memory Loss.
May 09, 2011: Neuren Completes First Patient Cohort In NNZ-2566 Phase II Clinical Trial
Aug 03, 2006: Neuren Selects New Compound Targeted For The Oral Treatment Of Parkinson's And Related Neurological Diseases
Jul 01, 2009: NNZ-2566 Development Overview July 2009
Financial Deals Landscape
Neuren Pharmaceuticals Limited, Deals Summary
Neuren Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Hamilton Pharmaceuticals Secures $11 Million In Series A Financing Round
Partnerships
Neuren Enters Into An Agreement With University Of Cambridge
Neuren Enters Into Collaboration Agreement With Bachem
Neuren Expands Collaboration With Walter Reed Army Institute
Neuren Pharmaceuticals Enters Into Research Agreement With Walter Reed
Neuren Enters Into Co-Development Agreement With Metabolic
Licensing Agreements
Neuren Pharmaceuticals Enters Into Licensing Agreement
Equity Offering
Neuren Pharmaceuticals Announces Private Placement Of Common Stock For $3.13 Million
Neuren Pharmaceuticals Completes Rights Issue Of Common Stock For $4.05 Million
Neuren Pharmaceuticals Completes Private Placement Of $2.2 Million
Neuren Pharmaceuticals Completes Private Placement Of $1.3 Million
Neuren Completes Private Placement Of $0.68 Million
Neuren Completes Rights Issue Of $6.1 Million
Neuren Pharmaceuticals Completes Rights Offering Of $1.23 Million
Neuren Completes Private Placement Of $4.5 Million
Neuren Completes Private Placement Of $4.7 Million
Debt Offering
Neuren Secures $6.75 Million In Funding
Neuren Pharmaceuticals Completes Private Placement Of Convertible Notes Of $3 Million
Acquisition
Neuren Pharmaceuticals Acquires Hamilton Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Neuren Pharmaceuticals Limited – Pipeline by Therapy Area and Indication, H2 2011
Neuren Pharmaceuticals Limited – Pipeline by Stage of Development, H2 2011
Neuren Pharmaceuticals Limited - Phase II, H2 2011
Neuren Pharmaceuticals Limited - Pipeline By Therapeutic Class, H2 2011
Neuren Pharmaceuticals Limited - Pipeline By Target, H2 2011
Neuren Pharmaceuticals Limited – Pipeline By Route of Administration, H2 2011
Neuren Pharmaceuticals Limited – Pipeline By Molecule Type, H2 2011
Neuren Pharmaceuticals Limited – Recent Pipeline Updates, H2 2011
Neuren Pharmaceuticals Limited - Dormant Developmental Projects, 2010
Neuren Pharmaceuticals Limited - Discontinued Pipeline Products, 2010
Neuren Pharmaceuticals Limited, Other Locations
Neuren Pharmaceuticals Limited, Subsidiaries
Neuren Pharmaceuticals Limited, Deals Summary
Hamilton Pharmaceuticals Secures $11 Million In Series A Financing Round
Neuren Enters Into An Agreement With University Of Cambridge
Neuren Enters Into Collaboration Agreement With Bachem
Neuren Expands Collaboration With Walter Reed Army Institute
Neuren Pharmaceuticals Enters Into Research Agreement With Walter Reed
Neuren Enters Into Co-Development Agreement With Metabolic
Neuren Pharmaceuticals Enters Into Licensing Agreement
Neuren Pharmaceuticals Announces Private Placement Of Common Stock For $3.13 Million
Neuren Pharmaceuticals Completes Rights Issue Of Common Stock For $4.05 Million
Neuren Pharmaceuticals Completes Private Placement Of $2.2 Million
Neuren Pharmaceuticals Completes Private Placement Of $1.3 Million
Neuren Completes Private Placement Of $0.68 Million
Neuren Completes Rights Issue Of $6.1 Million
Neuren Pharmaceuticals Completes Rights Offering Of $1.23 Million
Neuren Completes Private Placement Of $4.5 Million
Neuren Completes Private Placement Of $4.7 Million
Neuren Secures $6.75 Million In Funding
Neuren Pharmaceuticals Completes Private Placement Of Convertible Notes Of $3 Million
Neuren Pharmaceuticals Acquires Hamilton Pharmaceuticals

LIST OF FIGURES

Neuren Pharmaceuticals Limited – Pipeline by Therapy Area and Indication, H2 2011
Neuren Pharmaceuticals Limited – Pipeline by Stage of Development, H2 2011
Neuren Pharmaceuticals Limited – Pipeline By Therapeutic Class, H2 2011
Neuren Pharmaceuticals Limited – Pipeline By Route of Administration, H2 2011
Neuren Pharmaceuticals Limited – Pipeline By Molecule Type, H2 2011

Ask Your Question

Neuren Pharmaceuticals Limited – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: